Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,153 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03038308 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | completed | Phase 1 / Phase 2 | 16 | Columbia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03847519 | Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 24 | Advaxis, Inc.INDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03434262 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors |
| completed |
| Phase 1 |
| 68 |
| St. Jude Children's Research HospitalOTHER |
| 1 |
| May 31, 2024 |
| clinicaltrials |
| NCT05116007 | Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC | completed | Phase 1 | 35 | AkesoINDUSTRY | 1 | May 31, 2024 | clinicaltrials |
| NCT02834611 | Ceramide NanoLiposome in Patients With Advanced Solid Tumors | completed | Phase 1 | 14 | Keystone Nano, IncINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT02184533 | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | 15 | Stanford UniversityOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04400383 | Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors | completed | Phase 1 | 62 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT02164461 | Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer | completed | Phase 1 | 12 | Advaxis, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT03256344 | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | completed | Phase 1 | 36 | AmgenINDUSTRY | 6 | May 14, 2024 | clinicaltrials |
| NCT01941316 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 78 | Cancer Research and Biostatistics Clinical Trials ConsortiumNETWORK | 1 | May 9, 2024 | clinicaltrials |
| NCT04263090 | Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | completed | Phase 1 / Phase 2 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT02225405 | Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05864924 | A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma | completed | Phase 1 | 14 | BioSyngen Pte LtdINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT02312661 | Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer(OVMET) | completed | Phase 1 | 15 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03177460 | Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer | completed | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04216251 | PRevention Using EPA Against coloREctal Cancer(PREPARE) | completed | Phase 1 / Phase 2 | 81 | Massachusetts General HospitalOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT01447732 | Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 71 | Kyowa Kirin Co., Ltd.INDUSTRY | 0 | Apr 29, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT02705105 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 114 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02867007 | KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 36 | Kyowa Kirin, Inc.INDUSTRY | 2 | Apr 25, 2024 | clinicaltrials |
| NCT04444167 | A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04967079 | Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients | completed | Phase 1 | 33 | Shanghai Chest HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT00728390 | A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks | completed | Phase 1 | 74 | PfizerINDUSTRY | 3 | Apr 22, 2024 | clinicaltrials |
| NCT03330561 | PRS-343 in HER2-Positive Solid Tumors | completed | Phase 1 | 85 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03650348 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | completed | Phase 1 | 41 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT05046665 | Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients(ZiPUP) | completed | Phase 1 | 11 | South Metropolitan Health ServiceOTHER_GOV | 1 | Apr 22, 2024 | clinicaltrials |
| NCT05518201 | Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03470259 | Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging(TARGET) | completed | Phase 1 | 19 | University Medical Center GroningenOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT02516553 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | completed | Phase 1 | 174 | Boehringer IngelheimINDUSTRY | 6 | Apr 15, 2024 | clinicaltrials |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 146 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 12, 2024 | clinicaltrials |
| NCT03798639 | Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer | completed | Phase 1 | 7 | Claire VerschraegenOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03835533 | Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations(PORTER) | completed | Phase 1 | 43 | Parker Institute for Cancer ImmunotherapyOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03317119 | Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery | completed | Phase 1 | 26 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03490669 | Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 3 | Apr 5, 2024 | clinicaltrials |
| NCT04535323 | Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT02996825 | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | completed | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01761240 | Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC | completed | Phase 1 | 27 | MorphotekINDUSTRY | 1 | Mar 29, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02581787 | SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 28 | Maximilian DiehnOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT02273362 | Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | completed | Phase 1 / Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04134884 | Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer | completed | Phase 1 | 34 | Kathy MillerOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT05252364 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 22 | Hinova Pharmaceuticals Aus Pty LtdINDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT03373188 | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | completed | Phase 1 | 10 | Emory UniversityOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02762006 | Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma | completed | Phase 1 | 29 | Moshe OrnsteinOTHER | 1 | Mar 18, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Jun 4, 2024source: clinicaltrials